Literature DB >> 22585578

Comorbidity and disease burden in the National Comorbidity Survey Replication (NCS-R).

Anne M Gadermann1, Jordi Alonso, Gemma Vilagut, Alan M Zaslavsky, Ronald C Kessler.   

Abstract

BACKGROUND: Disease burden estimates rarely consider comorbidity. Using a recently developed methodology for integrating information about comorbidity into disease burden estimates, we examined the comparative burdens of nine mental and 10 chronic physical disorders in the National Comorbidity Survey Replication (NCS-R).
METHODS: Face-to-face interviews in a national household sample (n = 5,692) assessed associations of disorders with scores on a visual analog scale (VAS) of perceived health. Multiple regression analysis with interactions for comorbidity was used to estimate these associations. Simulation was used to estimate incremental disorder-specific effects adjusting for comorbidity.
RESULTS: The majority of respondents (74.9%) reported one or more disorders. Of respondents with disorders, 73.8-98.2% reported having at least one other disorder. The best-fitting model to predict VAS scores included disorder main effects and interactions for number of disorders. Adjustment for comorbidity reduced individual-level disorder-specific burden estimates substantially, but with considerable between-disorder variation (0.07-0.69 ratios of disorder-specific estimates with and without adjustment for comorbidity). Four of the five most burdensome disorders at the individual level were mental disorders based on bivariate analyses (panic/agoraphobia, bipolar disorder, posttraumatic stress disorder, major depression) but only two based on multivariate analyses, adjusting for comorbidity (panic/agoraphobia, major depression). Neurological disorders, chronic pain conditions, and diabetes were the other most burdensome individual-level disorders. Chronic pain conditions, cardiovascular disorders, arthritis, insomnia, and major depression were the most burdensome societal-level disorders.
CONCLUSIONS: Adjustments for comorbidity substantially influence estimates of disease burden, especially those of mental disorders, underlining the importance of including information about comorbidity in studies of mental disorders.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22585578      PMCID: PMC4005614          DOI: 10.1002/da.21924

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  45 in total

1.  Valuations of EQ-5D health states: are the United States and United Kingdom different?

Authors:  Jeffrey A Johnson; Nan Luo; James W Shaw; Paul Kind; Stephen Joel Coons
Journal:  Med Care       Date:  2005-03       Impact factor: 2.983

2.  Cost of disorders of the brain in Europe.

Authors:  Patrik Andlin-Sobocki; Bengt Jönsson; Hans-Ulrich Wittchen; Jes Olesen
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

3.  Testing the interval-level measurement property of multi-item visual analogue scales.

Authors:  Paul F M Krabbe; Peep F M Stalmeier; Leida M Lamers; Jan J V Busschbach
Journal:  Qual Life Res       Date:  2006-09-20       Impact factor: 4.147

4.  Multimorbidity's many challenges.

Authors:  Martin Fortin; Hassan Soubhi; Catherine Hudon; Elizabeth A Bayliss; Marjan van den Akker
Journal:  BMJ       Date:  2007-05-19

Review 5.  Is there a case for using visual analogue scale valuations in cost-utility analysis?

Authors:  David Parkin; Nancy Devlin
Journal:  Health Econ       Date:  2006-07       Impact factor: 3.046

6.  Prevalence of multimorbidity among adults seen in family practice.

Authors:  Martin Fortin; Gina Bravo; Catherine Hudon; Alain Vanasse; Lise Lapointe
Journal:  Ann Fam Med       Date:  2005 May-Jun       Impact factor: 5.166

7.  Impact of psychiatric disorders on health-related quality of life: general population survey.

Authors:  Samuli I Saarni; Jaana Suvisaari; Harri Sintonen; Sami Pirkola; Seppo Koskinen; Arpo Aromaa; Jouko Lönnqvist
Journal:  Br J Psychiatry       Date:  2007-04       Impact factor: 9.319

8.  Summary health statistics for the U.S. population: National Health Interview Survey, 2000.

Authors:  Charlotte A Schoenborn; Patricia F Adams; Jeannine S Schiller
Journal:  Vital Health Stat 10       Date:  2003-11

Review 9.  Framework for evaluating disease severity measures in older adults with comorbidity.

Authors:  Cynthia M Boyd; Carlos O Weiss; Jeff Halter; K Carol Han; William B Ershler; Linda P Fried
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2007-03       Impact factor: 6.053

10.  Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys.

Authors:  Josep Maria Haro; Saena Arbabzadeh-Bouchez; Traolach S Brugha; Giovanni de Girolamo; Margaret E Guyer; Robert Jin; Jean Pierre Lepine; Fausto Mazzi; Blanca Reneses; Gemma Vilagut; Nancy A Sampson; Ronald C Kessler
Journal:  Int J Methods Psychiatr Res       Date:  2006       Impact factor: 4.035

View more
  55 in total

1.  Disease Burden Among Individuals with Severe Mental Illness in a Community Setting.

Authors:  Kristin R Baughman; Natalie Bonfine; Sara E Dugan; Richard Adams; Mary Gallagher; R Scott Olds; Elizabeth Piatt; Christian Ritter
Journal:  Community Ment Health J       Date:  2015-11-26

2.  Which mental disorders are associated with the greatest impairment in functioning?

Authors:  Mark J Edlund; Jiantong Wang; Kristen Gulledge Brown; Valerie L Forman-Hoffman; Sara L Calvin; Sarra L Hedden; Jonaki Bose
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-06-29       Impact factor: 4.328

3.  Acid-sensing T cell death associated gene-8 receptor expression in panic disorder.

Authors:  Jeffrey R Strawn; Lauren L Vollmer; Katherine M J McMurray; Jeffrey A Mills; Sarah A Mossman; Sara T Varney; Heidi K Schroeder; Renu Sah
Journal:  Brain Behav Immun       Date:  2017-07-20       Impact factor: 7.217

4.  The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Authors:  Risë B Goldstein; Sharon M Smith; S Patricia Chou; Tulshi D Saha; Jeesun Jung; Haitao Zhang; Roger P Pickering; W June Ruan; Boji Huang; Bridget F Grant
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-04-22       Impact factor: 4.328

5.  Impact of depression on the intensity of patient navigation for women with abnormal cancer screenings.

Authors:  Ignacio I De La Cruz; Karen M Freund; Tracy A Battaglia; Clara A Chen; Sharon Bak; Richard Kalish; Barbara Lottero; Patrick Egan; Tim Heeren; Andrea C Kronman
Journal:  J Health Care Poor Underserved       Date:  2014-02

6.  Blockade of the GLT-1 Transporter in the Central Nucleus of the Amygdala Induces both Anxiety and Depressive-Like Symptoms.

Authors:  Catherine S John; Elizabeth I Sypek; William A Carlezon; Bruce M Cohen; Dost Öngür; Anita J Bechtholt
Journal:  Neuropsychopharmacology       Date:  2015-01-14       Impact factor: 7.853

7.  ApoE2 Exaggerates PTSD-Related Behavioral, Cognitive, and Neuroendocrine Alterations.

Authors:  Lance A Johnson; Damian G Zuloaga; Erin Bidiman; Tessa Marzulla; Sydney Weber; Helane Wahbeh; Jacob Raber
Journal:  Neuropsychopharmacology       Date:  2015-05-10       Impact factor: 7.853

Review 8.  Evaluating psychosocial contributions to chronic pain outcomes.

Authors:  S M Meints; R R Edwards
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-01-31       Impact factor: 5.067

9.  Evaluation of Candidate Items for Severe PTSD Screening for Patients With Chronic Pain: Pilot Data Analysis With the IRT Approach.

Authors:  Dokyoung S You; Maisa S Ziadni; Gadi Gilam; Beth D Darnall; Sean C Mackey
Journal:  Pain Pract       Date:  2019-11-21       Impact factor: 3.183

10.  Concurrent varenicline and prolonged exposure for patients with nicotine dependence and PTSD: A randomized controlled trial.

Authors:  Edna B Foa; Anu Asnaani; David Rosenfield; Laurie J Zandberg; Peter Gariti; Patricia Imms
Journal:  J Consult Clin Psychol       Date:  2017-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.